Icos was once the great hope for Seattle biotech. Founded in 1990 with investment from Bill Gates and inspirational leadership from George Rathmann, it went on over the next 15 years to assemble a team of 700 employees and create a $1 billion molecule. For a while, it looked like it would survive as the only big, independent, profitable biotech company in the Seattle area. The story didn’t unfold that way, as Eli Lilly bought the company for $2.3 billion in 2007 and gave pink slips to most of the local workforce. Some Icos alumni stayed on to help build CMC Biologics, and some left the region for new opportunities. But many talented scientists and businesspeople have stayed in the Northwest, building the next generation of Seattle life sciences companies. Come join Xconomy on November 27 as we bring together some of the leading Icosahedrons (yes, there’s a trivia question there) for a lively evening of war stories, networking, and thinking about what’s ahead for Seattle biotech.
Confirmed Speakers:
- Stephanie Florio
- Scientist, Infectious Disease Research Institute
- Mike Gallatin
- Senior Advisor, Frazier Healthcare Ventures
- Patrick Gray
- Scientific Fellow, Omeros
- Mila Lobanova
- VP of Finance and Operations, Blaze Bioscience
- Johnny Stine
- Founder, North Coast Biologics
- Cliff Stocks
- CEO, Theraclone Sciences
- Susan Sullivan
- Vice President of Project Management, CMC Biologics
- Gary Wilcox
- CEO, Cocrystal Discovery
- Albert Yu
- Vice President of Clinical Development, Omeros
Follow us on Twitter:
@Xconomy
#xcicos
Schedule:
Registration & Networking: 5:00 – 6:00 pm
Program: 6:00 – 6:35 pm
Networking reception: 6:35 – 8:00 pm
Full agenda here
Registration Information
Regular Registration: $50
Student Registration: $25
At the Door: $75
